title: Stimulatory type A CpG-DNA induces a Th2-like response in human endothelial cells.
abstract: Unmethylated CpG-DNA motifs from pathogens are detected by the pattern recognition receptor toll-like receptor 9 (TLR9), eliciting an inflammatory immune response. These DNA sequences have been identified as potent immune modifiers and are used as adjuvants in vaccine research. Since we previously found TLR9 expression and function in human endothelial cells, we have here investigated whether endothelial cells play a role in the recognition of respective ligands and whether their response might contribute to vaccination success. We determined the effect of CpG-DNA on the inflammatory response of human endothelial cells of aortic or skin microvascular origin (HAoEC, HDMEC and HMEC-1) and compared the effects to those of two identically treated human macrophage cell lines. Using the same CpG-DNA D19(chimera) sequence in both cell types, we find the known up-regulation of pro-inflammatory cytokines in macrophages but consistent and significant inhibition of the pro-inflammatory response (IL-6, IL-8, and IFN-beta1) in endothelial cells. This inhibition is accompanied by enhanced proliferation and an increase in IL-10 gene expression. This anti-inflammatory response persists even in the presence of pro-inflammatory cytokines and low LPS concentrations, and is overruled only in the presence of relatively high concentrations of LPS. By testing different sequences, we find the strongest response with phosphorothioate bonds. Our results demonstrate an important regulatory function of endothelial cells in inflammatory responses, and the apparent Th2-like endothelial response in the human system may contribute significantly to the adjuvant activity of CpG-DNA.
authors.affiliation: Institute of Molecular Medicine, Research Group Immunobiology, Heinrich-Heine-University, 40204 Duesseldorf, Germany. nicole.fitzner@uni-duesseldorf.de
authors.forename: N
authors.initials: N
authors.lastname: Fitzner
authors.forename: L
authors.initials: L
authors.lastname: Zahner
authors.forename: C
authors.initials: C
authors.lastname: Habich
authors.forename: V
authors.initials: V
authors.lastname: Kolb-Bachofen
mesh_terms: D000276:Adjuvants, Immunologic / Q000235:genetics / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D018899:CpG Islands / Q000276:immunology; D042783:Endothelial Cells / Q000187:drug effects* / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects; D016899:Interferon-beta / Q000037:antagonists & inhibitors; D016753:Interleukin-10 / Q000235:genetics; D016209:Interleukin-8 / Q000037:antagonists & inhibitors; D008024:Ligands; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology; D009838:Oligodeoxyribonucleotides / Q000235:genetics / Q000494:pharmacology*; D060888:Real-Time Polymerase Chain Reaction; D018418:Th2 Cells / Q000187:drug effects* / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000276:immunology; D000093242:Interleukin-6 Inhibitors; D015850:Interleukin-6
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D016753:Interleukin-10; D016209:Interleukin-8; D008024:Ligands; D009838:Oligodeoxyribonucleotides; D051217:Toll-Like Receptor 9; D000093242:Interleukin-6 Inhibitors; C408982:CPG-oligonucleotide; C508600:IL6 protein, human; D015850:Interleukin-6; C495371:TLR9 protein, human